ATE332710T1 - GROWTH INHIBITOR AGAINST LEUKEMIC CELLS CONTAINING ANTISENSE OLIGONUCLEOTIDE DERIVATIVES AGAINST WILMS TUMOR - Google Patents
GROWTH INHIBITOR AGAINST LEUKEMIC CELLS CONTAINING ANTISENSE OLIGONUCLEOTIDE DERIVATIVES AGAINST WILMS TUMORInfo
- Publication number
- ATE332710T1 ATE332710T1 AT96914430T AT96914430T ATE332710T1 AT E332710 T1 ATE332710 T1 AT E332710T1 AT 96914430 T AT96914430 T AT 96914430T AT 96914430 T AT96914430 T AT 96914430T AT E332710 T1 ATE332710 T1 AT E332710T1
- Authority
- AT
- Austria
- Prior art keywords
- antisense oligonucleotide
- growth inhibitor
- cells containing
- oligonucleotide derivatives
- leukemic cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Abstract
A leukemic cell growth inhibitor containing antisense oligonucleotide derivatives against Wilms' tumor gene (WT1). <IMAGE>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15667295 | 1995-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE332710T1 true ATE332710T1 (en) | 2006-08-15 |
Family
ID=15632793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96914430T ATE332710T1 (en) | 1995-06-01 | 1996-05-24 | GROWTH INHIBITOR AGAINST LEUKEMIC CELLS CONTAINING ANTISENSE OLIGONUCLEOTIDE DERIVATIVES AGAINST WILMS TUMOR |
Country Status (7)
Country | Link |
---|---|
US (2) | US6034235A (en) |
EP (1) | EP0841068B1 (en) |
AT (1) | ATE332710T1 (en) |
AU (1) | AU5779696A (en) |
DE (1) | DE69636339T2 (en) |
ES (1) | ES2268705T3 (en) |
WO (1) | WO1996038176A1 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US7309692B1 (en) * | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
JP4789095B2 (en) | 1997-07-16 | 2011-10-05 | 治夫 杉山 | Solid tumor therapeutic agent comprising an expression inhibitor against Wilms tumor gene (WT1) |
US20030092656A1 (en) * | 1997-07-16 | 2003-05-15 | Haruo Sugiyama | Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1) |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
CA2337743C (en) * | 1998-07-31 | 2015-07-07 | Yoshihiro Oka | Tumor antigen based on products of the tumor suppressor gene wt1 |
US7329410B1 (en) | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
US20030215458A1 (en) * | 1998-09-30 | 2003-11-20 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7655249B2 (en) * | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7901693B2 (en) * | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7144581B2 (en) * | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20030039635A1 (en) * | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
WO2002006297A1 (en) * | 2000-07-19 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Novel antisense oligonucleotide derivatives against wilms's tumor gene |
ES2298353T3 (en) * | 2001-03-22 | 2008-05-16 | International Institute Of Cancer Immunology, Inc. | MODIFIED WT1 PEPTIDE. |
US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
CA2471967A1 (en) * | 2002-01-03 | 2003-07-31 | Board Of Regents, The University Of Texas System | Wt1 antisense oligos for the inhibition of breast cancer |
WO2003106682A1 (en) * | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Hla-a24-restricted cancer antigen peptide |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
AU2003262094A1 (en) * | 2002-09-12 | 2004-04-30 | Haruo Sugiyama | Cancer antigen peptide preparation |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
DE602004023476D1 (en) | 2003-01-15 | 2009-11-19 | Chugai Pharmaceutical Co Ltd | DIMERIZED PEPTIDE |
KR101224235B1 (en) | 2003-04-11 | 2013-01-25 | 메디뮨 엘엘씨 | Recombinant IL-9 Antibodies and Uses Thereof |
EP2272566A3 (en) | 2003-08-18 | 2013-01-02 | MedImmune, LLC | Humanisation of antibodies |
WO2005087260A1 (en) * | 2004-03-04 | 2005-09-22 | Corixa Corporation | Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof |
JP4762133B2 (en) * | 2004-03-29 | 2011-08-31 | 治夫 杉山 | MicroRNA that suppresses expression of WT1 gene and use thereof |
EP1741786A4 (en) * | 2004-03-29 | 2007-05-09 | Haruo Sugiyama | Method of separating precusror cells of liver cells, endothelial cells or hematopoietic cells from cell mass |
EP1738771A4 (en) | 2004-03-29 | 2010-04-21 | Haruo Sugiyama | siRNA CAPABLE OF INHIBITING EXPRESSION OF WT1 GENE AND USE THEREOF |
EP1755673B1 (en) | 2004-04-12 | 2014-07-23 | MedImmune, LLC | Anti-il-9 antibody formulations and uses thereof |
CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
FR2877350B1 (en) * | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION AND USE OF miRNAs INVOLVED IN THE DIFFERENTIATION OF CELLS FROM MYELOID LEUKEMIA |
JP5153613B2 (en) | 2005-03-18 | 2013-02-27 | メディミューン,エルエルシー | Antibody framework shuffle |
KR20080025174A (en) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | Antibody formulations having optimized aggregation and fragmentation profiles |
KR20070101610A (en) * | 2006-04-11 | 2007-10-17 | 주식회사 바이오인프라 | Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent |
US8399426B2 (en) * | 2006-04-11 | 2013-03-19 | Bioinfra Inc. | Method for treating breast cancer using adenine nucleotide translocator 2 (ANT2) siRNA or ANT2 shRNA |
EP2064243A2 (en) | 2006-08-28 | 2009-06-03 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic human light-specific human monoclonal antibodies |
JP5456658B2 (en) | 2007-03-30 | 2014-04-02 | メディミューン,エルエルシー | Antibody preparation |
RU2010121967A (en) | 2007-10-31 | 2011-12-10 | Медиммун, Ллк (Us) | PROTEIN FRAME FRAME STRUCTURES |
EP2668210B1 (en) | 2011-01-26 | 2020-06-17 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
US9334332B2 (en) | 2012-07-25 | 2016-05-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
WO2014059028A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
SG11201509982UA (en) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
EP3229838B1 (en) | 2014-12-11 | 2020-09-09 | Pierre Fabre Medicament | Anti-c10orf54 antibodies and uses thereof |
WO2016139482A1 (en) | 2015-03-03 | 2016-09-09 | Kymab Limited | Antibodies, uses & methods |
AU2016365318B2 (en) | 2015-12-02 | 2024-04-18 | Board Of Regents, The University Of Texas System | Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof |
KR20180100122A (en) | 2015-12-02 | 2018-09-07 | 주식회사 에스티사이언스 | Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor) |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
EP3630834A1 (en) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
EP3630835A1 (en) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
CN110997724A (en) | 2017-06-06 | 2020-04-10 | 斯特库伯株式会社 | Methods of treating cancer using antibodies and molecules that bind BTN1A1 or BTN1A 1-ligands |
BR112021000934A2 (en) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receiver for sight |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1536392A (en) * | 1991-01-18 | 1992-08-27 | Oncogene Science, Inc. | Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes |
US5622835A (en) * | 1994-04-28 | 1997-04-22 | The Wistar Institute Of Anatomy & Biology | WT1 monoclonal antibodies |
-
1996
- 1996-05-24 WO PCT/JP1996/001394 patent/WO1996038176A1/en active IP Right Grant
- 1996-05-24 US US08/952,664 patent/US6034235A/en not_active Expired - Lifetime
- 1996-05-24 ES ES96914430T patent/ES2268705T3/en not_active Expired - Lifetime
- 1996-05-24 DE DE69636339T patent/DE69636339T2/en not_active Expired - Lifetime
- 1996-05-24 AT AT96914430T patent/ATE332710T1/en not_active IP Right Cessation
- 1996-05-24 AU AU57796/96A patent/AU5779696A/en not_active Abandoned
- 1996-05-24 EP EP96914430A patent/EP0841068B1/en not_active Expired - Lifetime
-
2000
- 2000-01-20 US US09/487,874 patent/US6277832B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6277832B1 (en) | 2001-08-21 |
DE69636339T2 (en) | 2007-07-19 |
WO1996038176A1 (en) | 1996-12-05 |
DE69636339D1 (en) | 2006-08-24 |
US6034235A (en) | 2000-03-07 |
EP0841068A1 (en) | 1998-05-13 |
EP0841068B1 (en) | 2006-07-12 |
AU5779696A (en) | 1996-12-18 |
ES2268705T3 (en) | 2007-03-16 |
EP0841068A4 (en) | 2004-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE332710T1 (en) | GROWTH INHIBITOR AGAINST LEUKEMIC CELLS CONTAINING ANTISENSE OLIGONUCLEOTIDE DERIVATIVES AGAINST WILMS TUMOR | |
TR200002445T2 (en) | Phospholipase inhibitors. | |
MY120235A (en) | Aryloxyarylsulfonylamino hydroxamic acid derivatives | |
DE69421476T2 (en) | Electrochemical immunosensor system | |
DE69404291D1 (en) | IMPROVEMENTS REGARDING ELECTROCHEMICAL CELLS | |
HUP0104681A3 (en) | Human hybrid host cell for mammalian gene expression | |
ATE320491T1 (en) | OPTIMIZATION OF CELLS FOR ENDOGENEOUS GENE ACTIVATION | |
AU8286998A (en) | Genes for niemann-pick type c disease | |
ITRM960385A0 (en) | ELECTROLYTIC CELL | |
DE69941869D1 (en) | SPECIFIC GENES OF THE BASIC ENDOSPERM TRANSFER CELL LAYER (BETL) | |
DE69613016D1 (en) | Electrochemical cell | |
TR199802648A3 (en) | Nucleic acid constructs for gene therapy. | |
DE59607589D1 (en) | N-ARYL-1,2,4-TRIAZOLINE-5-ONE | |
AU8243198A (en) | Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors | |
DK1135513T4 (en) | Adenovirus-mediated gene therapy | |
GR3024191T3 (en) | Fluoro-compounds and their use as aromatase inhibitors | |
ES2181677T3 (en) | METHOD AND USEFUL COMPOSITIONS IN CELLULAR REPROGRAMATION. | |
DE59602409D1 (en) | ELECTROLYTE CELL | |
FI951760A (en) | Gestagent acting 19,11-crosslinked 4-estrener | |
DE59108566D1 (en) | Heteroarylmethylbenzenes aromatase inhibitors | |
ATE346616T1 (en) | LABELED ASCORBIC ACID DERIVATIVES | |
FI854284A0 (en) | FOERFARANDE FOER FRAMSTAELLNING AV OPTISKT ACTIVE AZOLYLCARBINOLDERIVAT, ENOUGH DETTA FOERFARANDE FRAMSTAELLD OPTISKT AKTIV 2- (4-CHLORPHENOXIMETHYL) -3,3-DIMETHYL-O-DES-B-YL-1-THIAZOL SOM ANTIMYKOTIKUM. | |
AU3068099A (en) | Chromosome 11-linked coronary heart disease susceptibility gene chd1 | |
AU4765599A (en) | Lafora's disease gene | |
FI902353A0 (en) | BIOLOGICAL COMPOSITION AVERAGE FOR THE PURPOSE OF A GENE TILLSAETNING AV HORMONALISKA LAEKEMEDEL I FOER VARJE DJUR SAEREGEN BETESTYP. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |